Back to top
more

Vericel (VCEL)

(Delayed Data from NSDQ)

$46.11 USD

46.11
199,486

-0.31 (-0.67%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $46.07 -0.04 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Vericel Corporation (VCEL) Q4 Earnings Beat Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 44.44% and 0%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Are You Looking for a Top Momentum Pick? Why Vericel Corporation (VCEL) is a Great Choice

Does Vericel Corporation (VCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline

Y-mAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vericel Corporation (VCEL) to Report Q4 Results: Wall Street Expects Earnings Growth

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vericel Corporation (VCEL) is on the Move, Here's Why the Trend Could be Sustainable

If you are looking for stocks that are well positioned to maintain their recent uptrend, Vericel Corporation (VCEL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Recent Price Trend in Vericel Corporation (VCEL) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Vericel Corporation (VCEL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Vericel Corporation (VCEL) Moves 7.0% Higher: Will This Strength Last?

Vericel Corporation (VCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Vericel Corporation (VCEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ensign Group (ENSG) Surpasses Q3 Earnings and Revenue Estimates

Ensign Group (ENSG) delivered earnings and revenue surprises of 1.69% and 0.20%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Ideas feature highlights: Fresenius Medical Care, Vericel and ImmunoGen

Fresenius Medical Care, Vericel and ImmunoGen are part of the Zacks Investment Ideas article.

Shaun Pruitt headshot

Top Medical Stocks to Buy Amid Recent Market Volatility

Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare is always essential.

New Strong Buy Stocks for October 23rd

MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.

New Strong Buy Stocks for October 19th

INTA, NU, ENLV, VCEL and BIVI have been added to the Zacks Rank #1 (Strong Buy) List on October 19, 2023.

Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 15.38% and 7.27%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of 24.44% and 32.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -23.08% and 6.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 1.19% and 19.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of 2.75% and 6.31%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 28.93% and 3.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) Surges 8.4%: Is This an Indication of Further Gains?

Allogene Therapeutics (ALLO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Vericel Corporation (VCEL) Q4 Earnings Surpass Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 500% and 0.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?

Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Vericel Corporation (VCEL) Reports Q3 Loss, Lags Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -16.67% and 3.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 23.40% and 44.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?